加速“侵入式”脑机接口研发，智冉医疗融资超3亿元

Core Insights - Zhiran Medical, a hard-tech company based in Haidian, Beijing, has completed over 300 million yuan in Series A financing to accelerate the development of its next-generation invasive flexible brain-computer interface (BCI) platform [1] - The financing round was led by the Social Security Fund's Zhongguancun Independent Innovation Special Fund, Junlian Capital, and IDG Capital, with participation from existing shareholders and other investors [1] - The company aims to use the funds primarily for advancing technology development and conducting large-scale clinical trials [1] Company Overview - Zhiran Medical was founded in 2022 and has raised nearly 500 million yuan in total funding, reflecting market recognition of its technology and commercialization prospects [1] - The founder and chief scientist, Fang Ying, is a researcher at the Beijing Brain Science and Brain-like Research Institute, while the CEO, Song Qi, is a serial entrepreneur with experience in AI medical enterprises [1] Industry Context - The concept of brain-computer interfaces (BCI) has gained significant attention recently due to advancements in high-bandwidth human-computer interaction, particularly through invasive BCI technology [2] - Invasive BCIs offer unique advantages in high-throughput, high-resolution signal acquisition, and precise neural modulation compared to non-invasive and semi-invasive technologies [2] - The development of invasive BCI technology is seen as a key to unlocking a new era of high-throughput human-computer interaction, similar to how deep neural networks revolutionized the AI field [2] Technological Development - Zhiran Medical has focused on the challenging route of invasive BCI technology, similar to the approach taken by international competitor Neuralink [2] - The company has developed proprietary invasive high-throughput flexible electrodes that have received patent authorization in both China and the United States, utilizing ultra-thin flexible materials to minimize brain damage during implantation [2] - The team has established a comprehensive system for invasive BCI, including hardware, software, decoding algorithms, and implantation robots, along with a clinical-grade micro-nano processing workshop and GMP facility to ensure product quality and safety [3]